• In the past quarter, Harmony Biosciences Holdings, Inc. reported second-quarter 2026 net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69.
• For the first half of 2026, Harmony’s net income increased to US$107.92 million from US$85.34 million, highlighting stronger profitability while it continues advancing therapies for rare neurological diseases.
• With this sharp year-on-year earnings jump and ongoing neurology pipeline progress, we’ll examine how the latest results reshape Harmony’s investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Harmony Biosciences Holdings Investment Narrative Recap

To own Harmony Biosciences, you have to believe WAKIX can keep funding a broader rare neurology business while the pipeline gradually reduces dependence on a single drug. The sharp Q2 2026 earnings jump strengthens the near term story, but it does not change the core tension between strong current cash generation and the concentration risk around WAKIX as competition and patent timelines approach.

The most relevant recent development alongside these results is Harmony’s reiterated 2026 net product revenue guidance of US$1.0 billion to US$1.04 billion. Holding that outlook steady after reporting higher year on year earnings suggests management sees the quarter as supporting, rather than redefining, its near term targets. For investors, the key question is whether current WAKIX performance can consistently backstop that revenue range while the neurology pipeline matures.

Yet beneath the solid Q2 and upbeat guidance, investors still need to be aware of how exposed Harmony remains to one drug as...

Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028.

Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenues near US$1.7 billion and earnings around US$486 million by 2029, so this earnings beat could either reinforce those views or prompt a rethink, depending on how you weigh WAKIX reliance versus future pipeline success.

Explore 4 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.